IP Library Granted Patent US 8,933,222
Granted Patent B2
US 8,933,222 · App. 14/197,771 · Granted Jan 13, 2015

Oxadiazoanthracene compounds for the treatment of diabetes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,933,222
App. No.
14/197,771
Granted
Jan 13, 2015
Kind
B2
Abstract

The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R 1 , R 2 , R 3 , R 4 and R 5 are as herein described, and methods of synthesizing precursors to these oxadiazoanthracene derivatives.

Claims (123)

1. A method of synthesizing a compound of the following formula

comprising coupling a compound of formula XX

with an amine compound of the formula

or an acid salt thereof;

wherein

R is —(CH 2 ) p -G 1 -L 1 -G 2 , wherein

L 1 is selected from the group consisting of: a direct bond, —CH 2 —, —O—, —N(R 16 )—, —C(O)—, —CON(R 16 )—, —N(R 16 )C(O)—, —N(R 16 )SO 2 —, —SO 2 N(R 16 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, and —C≡C—, wherein

R 16 is selected from the group consisting of: -hydrogen, -alkyl, -aryl, -alkylene-aryl;

G 1 is selected from the group consisting of: alkynylene, arylene, heteroarylene, fused arylcycloalkylene, fused cycloalkylarylene, fused cycloalkylheteroarylene, fused heterocyclylarylene, and fused heterocyclylheteroarylene, wherein G 1 is optionally substituted 1-4 times with substituents independently selected from R 10 , wherein

R 10 is Rb,

G 2 is selected from the group consisting of: -aryl, -heteroaryl, -fused arylcycloalkyl, -fused cycloalkylaryl, -fused cycloalkylheteroaryl, -fused heterocyclylaryl, and -fused heterocyclylheteroaryl, wherein G 2 is optionally substituted 1-4 times with substituents independently selected from R 11 , wherein

R 11 is Rb,

R 1 is —CO 2 R 12 , wherein R 12 is selected from the group consisting of: —C 1-10 alkyl, -cycloalkyl, and -aryl, wherein R 12 is optionally substituted 1-4 times with a group independently selected from R c ;

R 2 is hydrogen;

R 3 is selected from R a ;

R 5 is -G 3 -L 2 -Q 2 -L 3 -G 4 , wherein

L 2 and L 3 are independently selected from the group consisting of: a direct bond, —CH 2 —, —O—, —N(R 26 )—, —C(O)—, —CON(R 26 )—, —N(R 26 )C(O)—, —N(R 26 )CON(R 27 )—, —N(R 26 )C(O)O—, —OC(O)N(R 26 )—, —N(R 26 )SO 2 —, —SO 2 N(R 26 )—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O) 2 —, and —N(R 26 )SO 2 N(R 27 )—, wherein

R 26 and R 27 are independently selected from the group consisting of: hydrogen, -alkyl, -aryl, and -alkylene-aryl, wherein R 26 and R 27 are optionally substituted 1-4 times with R c , or R 26 and R 27 are taken together with the atoms to which they are attached to form a heterocyclic ring of 5 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, nitrogen, and sulfur;

Q 2 is selected from the group consisting of: a direct bond, C 1-10 alkylene, C 2-10 alkenylene, and C 2-10 alkynylene,

G 3 is selected from the group consisting of: -arylene, -cycloalkylene, -heterocyclylene, -heteroarylene, -fused arylcycloalkylene, -fused cycloalkylarylene, -fused cycloalkylheteroarylene, -fused heterocyclylarylene, and -fused heterocyclylheteroarylene, wherein

G 3 is optionally substituted 1-4 times with substituents independently selected from R 8 , wherein R 8 is selected from R b ,

G 4 is selected from the group consisting of: -aryl, -cycloalkyl, -heterocyclyl, -heteroaryl, -fused arylcycloalkyl, -fused cycloalkylaryl, -fused cycloalkylheteroaryl, -fused heterocyclylaryl, and -fused heterocyclylheteroaryl, wherein

G 4 is optionally substituted 1-4 times with substituents independently selected from R 9 , wherein R 9 is selected from R b ,

R a is selected from the group consisting of:

a) -hydrogen,

b) —S(O) m R d ,

c) —S(O) 2 OR d ,

d) —S(O) m NR d R e ,

e) —C(O)R d ,

f) —CO 2 R d ,

g) —C(O)NR d R e ,

h) -haloalkyl,

i) -cycloalkyl,

j) -heterocyclyl,

k) —C 1-10 alkyl,

l) —C 2-10 alkenyl,

m) —C 2-10 alkynyl,

n) -aryl,

o) -heteroaryl,

p) —C 1-10 alkylene-aryl,

q) —C 2-10 alkynylene-aryl,

r) —C 1-10 alkylene-heteroaryl,

s) —C 2-10 alkynylene-heteroaryl, and

t) —C(R f R g ) n -aryl,

wherein alkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, and cycloalkyl groups are optionally substituted 1-4 times with a group independently selected from R c ;

R b is selected from the group consisting of:

a) -cycloalkyl,

b) -cyano,

c) —OR d ,

d) —NO 2 ,

e) -halogen,

f) —S(O) m R d ,

g) —SR d ,

h) —S(O) 2 OR d ,

i) —S(O) m NR d R e ,

j) —NR d R e ,

k) —O(CR f R g ) n NR d R e ,

l) —C(O)R d ,

m) —CO 2 R d ,

n) —CO 2 (CR f R g ) n CONR d R e ,

o) —OC(O)R d ,

p) —C(O)NR d R e ,

q) —NR d C(O)R e ,

r) —OC(O)NR d R e ,

s) —NR d C(O)OR e ,

t) —NR d C(O)NR d R e ,

u) —CF 3 ,

v) —OCF 3 ,

w) -haloalkyl,

x) -haloalkoxy,

y) —C 1-10 alkyl,

z) —C 2-10 alkenyl,

aa) —C 2-10 alkynyl,

ab) —C 1-10 alkylene-aryl,

ac) —C 1-10 alkylene-heteroaryl, and

ad) -heteroaryl,

wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl, and cycloalkyl groups are optionally substituted 1-4 times with a group independently selected from R c ;

R c is selected from the group consisting of:

a) -halogen,

c) -amino,

c) -carboxy,

d) -cyano,

e) —C 1-4 alkyl,

f) —O—C 1-4 alkyl,

g) —O—CF 3 ,

h) -cycloalkyl,

i) —O-cycloalkyl,

j) -aryl,

k) —C 1-4 alkylene-aryl,

l) -hydroxy,

m) —CF 3 ,

n) -haloalkyl,

o) -haloalkoxy,

p) —O-aryl,

q) -heteroaryl,

r) -heteroarylene-C 1-10 alkyl,

s) -heterocyclyl,

t) —CO 2 —C 1-10 alkyl,

u) —CO 2 —C 1-10 alkyl-aryl,

v) -fused arylcycloalkyl,

w) -alkynylene-heteroaryl,

x) -alkylene-aryl,

y) -alkynylene-aryl,

z) -nitro,

aa) —N(H)—C(O)—C 1-6 -alkyl, and

bb) —S—C 1-6 -alkyl,

R d and R e are independently selected from the group consisting of: hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, cycloalkyl, —C 1-10 alkylene-cycloalkyl, aryl, heteroaryl, and heterocyclyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl groups are optionally substituted with one to four substituents independently selected from R c ; or R d and R e together with the atoms to which they are attached form a heterocyclic ring of 5 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and nitrogen and optionally substituted with 1-3 times with R c ,

R f and R g are independently selected from the group consisting of: hydrogen, C 1-10 alkyl, cycloalkyl, —C 1-10 alkylene-cycloalkyl, -carboxy, and aryl, wherein alkyl, cycloalkyl, and aryl groups are optionally substituted with one to four substituents independently selected from R c ; or R f and R g together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen optionally substituted with 1-3 times with R c ;

m is an integer from 1 to 2;

n is an integer from 1 to 10; and

p is an integer from 0 to 2.

2. The method of claim 1 , wherein the compound of formula XX and the amine compound are coupled in the presence of o-benzotriazol-1-yl-tetramethyluronium hexafluorophosphate (HBTU).

3. A method of synthesizing a compound of the following formula

comprising coupling a compound of formula XX

with an amine compound of the formula

or an acid salt thereof;

wherein

R is

R 1 is —CO 2 R 12 , wherein R 12 is methyl;

R 2 is hydrogen;

R 3 is —(R)-1-phenyl-propyl or —(S)-1-phenyl-propyl; and

R 5 is

4. The method of claim 3 , wherein the compound of formula XX and the amine compound are coupled in the presence of o-benzotriazol-1-yl-tetramethyluronium hexafluorophosphate (HBTU).

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Jan 27, 2021
From: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
To: VTV THERAPEUTICS LLC
Reel/Frame 055133/0214 →
SECURITY INTEREST Recorded Apr 18, 2018
From: VTV THERAPEUTICS LLC
To: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
Reel/Frame 045969/0774 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036254 FRAME: 0780. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 24, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS I LLC
Reel/Frame 036675/0407 →
RELEASE OF SECURITY INTEREST Recorded Aug 3, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS II LLC
Reel/Frame 036254/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: VTVX HOLDINGS I LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036242/0354 →
CHANGE OF NAME Recorded Jul 30, 2015
From: VTV THERAPEUTICS LLC
To: VTVX HOLDINGS I LLC
Reel/Frame 036236/0165 →
CHANGE OF NAME Recorded Jun 25, 2015
From: TRANSTECH PHARMA, LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036026/0219 →
SECURITY INTEREST Recorded Feb 26, 2015
From: TRANSTECH PHARMA, LLC
To: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
Reel/Frame 035103/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2014
From: MJALLI, ADNAN M.M.; POLISETTI, DHARMA RAO; YOKUM, THOMAS SCOTT; SANTHOSH, KALPATHY; GUZEL, MUSTAFA; BEHME, CHRISTOPHER; DAVIS, STEPHEN THOMAS
To: TRANSTECH PHARMA, INC.
Reel/Frame 032508/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2014
From: TRANSTECH PHARMA, INC.
To: TRANSTECH PHARMA, LLC
Reel/Frame 032508/0090 →